Lv4
440 积分 2026-03-27 加入
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial
4小时前
待确认
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial
19天前
已完结
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
1个月前
已完结
68Ga-PSMA PET/CT in Patients with Rising Prostatic-Specific Antigen After Definitive Treatment of Prostate Cancer: Detection Efficacy and Diagnostic accuracy
1个月前
已完结
Continence criteria of 193 618 patients after open, laparoscopic, and robot-assisted radical prostatectomy
1个月前
已完结
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration
1个月前
已完结
Oligometastatic prostate cancer: time to integrate metastasis-directed therapy
1个月前
已完结
Current Treatment Paradigms and Clinical Outcomes in Oligometastatic Prostate Cancer Patients: A Targeted Literature Review
1个月前
已完结
Age-stratified clinical outcomes and adverse events in patients with metastatic castration-sensitive prostate cancer receiving triplet therapy with darolutamide, androgen deprivation therapy, and docetaxel
2个月前
已完结
Triplet therapy versus androgen receptor pathway inhibitor-doublet therapy in metastatic castration-sensitive prostate cancer: a real-world multicenter retrospective comparison
2个月前
已完结
皖公网安备34019202002308
